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The general disruption of redox signaling following an ischemia-reperfusion episode has been proposed as a crucial
component in neuronal death and consequently brain damage. Thioredoxin (Trx) family proteins control redox reactions
and ensure protein regulation via specific, oxidative posttranslational modifications as part of cellular signaling processes.
Trx proteins function in the manifestation, progression, and recovery following hypoxic/ischemic damage. Here, we analyzed
the neuroprotective effects of postinjury, exogenous administration of Grx2 and Trx1 in a neonatal hypoxia/ischemia model. P7
Sprague-Dawley rats were subjected to right common carotid ligation or sham surgery, followed by an exposure to nitrogen. 1 h
later, animals were injected i.p. with saline solution, 10mg/kg recombinant Grx2 or Trx1, and euthanized 72 h postinjury.
Results showed that Grx2 administration, and to some extent Trx1, attenuated part of the neuronal damage associated with a
perinatal hypoxic/ischemic damage, such as glutamate excitotoxicity, axonal integrity, and astrogliosis. Moreover, these
treatments also prevented some of the consequences of the induced neural injury, such as the delay of neurobehavioral
development. To our knowledge, this is the first study demonstrating neuroprotective effects of recombinant Trx proteins on the
outcome of neonatal hypoxia/ischemia, implying clinical potential as neuroprotective agents that might counteract neonatal
hypoxia/ischemia injury.
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1. Introduction
One of the main causes of neonatal death and neurological
deficits in children is an insufficient oxygen supply during
birth, known as perinatal asphyxia (PA). The central nervous
system (CNS), particularly the brain, is damaged as a result of
the combination of hypoxia, blood flow reduction (ischemia),
and reoxygenation [1]. This pathology is associated with an
increase in the levels of glutamate [2] and the consequent
release of nitric oxide (NO) [3, 4]. Moreover, an increase of
the superoxide anion radical (O2-·) which can rapidly react
with NO to form peroxynitrite anions (ONOO-) has been
described [5]. The excess of these molecules and the unspe-
cific damage to various biomolecules have been described
as oxidative stress in the 80th and have been linked to cell
death, inflammation and might even explain the high
mortality risk. Nowadays, the definition of oxidative stress
has been paraphrased, acknowledging the function of differ-
ent reactive species in physiological signaling cascades as well
as their dysregulation in pathological conditions [6].
Redox signaling is regulated by proteins of the thiore-
doxin (Trx) family such as Trxs, glutaredoxins (Grxs) and
peroxiredoxins (Prxs), that use thiol groups of cysteinyl
residues within their active site motifs to catalyze for example
thiol-disulfide exchange reactions [7, 8] (for an overview, see
[6]). These redox proteins show tissue- and cell type-specific
distributions. For instance, our work demonstrates specific
differences in terms of protein abundance and distribution
in the murine CNS [9, 10]. Trx family proteins possess the
representative common structural motif, known as the Trx
fold [11]. Trxs and Grxs are small oxidoreductases that
contain the characteristic and highly conserved dithiol Cys-
X-X-Cys motif in their active site that is essential for the
reduction of specific disulfide bonds via the dithiol mecha-
nism. Moreover, Trxs can catalyze the de-/nitrosylation of
substrates and Grxs can catalyze the de-/glutathionylation
of target proteins via the monothiol mechanism (reviewed
in [12]). Trxs and Grxs can reduce Prxs, which are not only
highly abundant peroxidases but rather regulators of the
levels of the second messenger hydrogen peroxide and there-
fore essential for redox signaling [6, 12].
Interestingly, these proteins were shown to be altered in
terms of expression, cellular distribution, and/or activity in
various disorders. Also in diseases linked to hypoxia/ische-
mia, Trxs, Grxs, and Prxs and thereby cellular signaling
within distinct cell types and tissues are significantly altered
(for an overview, see [6]). Following cerebral ischemia
induced by middle cerebral artery occlusion, Trx1 was
reduced in ischemic areas and increased in perifocal ischemic
regions [13]. Trx1 was induced in hippocampal glial cells
during reperfusion following a transient cerebral ischemia
in gerbils [14]. Transgenic mice overexpressing human
Trx1 showed attenuated ischemic neuronal injury and signif-
icantly smaller infarct sizes when subjected to focal cerebral
ischemia [15]. Moreover, Trx1 overexpression was shown
to protect mice from neuronal apoptosis following mild
focal ischemia [16]. In accordance with this evidence, the
knock-down of Trx1 led to more pronounced neurological
dysfunction, brain infarct size, brain edema, and overall
peroxidation [17], as well as exacerbated apoptosis of neu-
rons, behavioral deficits, and mortality [18]. Interestingly,
the overexpression of the mitochondrial Trx2 attenuated
ROS-induced TNF-α expression and subsequent NF-κB
activation and apoptosis [19]. Additionally, the protein levels
of the cytosolic Grx1 were diminished after middle cerebral
artery occlusion, correlating with neuronal damage [20].
Moreover, the overexpression of Prx2 was shown to protect
cortical neuronal cell cultures from oxidative and ischemic
damage [21]. Furthermore, exogenous administration of
human Trx1 was shown to be able to pass the blood-brain
barrier and exert a positive effect on neurogenesis promotion
and cognitive recovery following cerebral ischemia in adult
mice [22].
We have recently shown an increase in the hippocampal
protein levels of Trx1 and Grx2 following a neonatal
hypoxic/ischemic event. The specific knock-down of these
proteins in a neuron-like cell model allowed us to characterize
the importance of these proteins in neuronal differentiation
and maturation after a hypoxic/ischemic reperfusion event.
Particularly, both Grx2 and Trx1 seem to protect neuronal
cells from hypoxia-induced damage, while Trx1 knock-
down decreases cellular proliferation and viability. Moreover,
the absence of either Grx2 or Trx1 following hypoxia and
reoxygenation triggers differentiation into a glial-like cell
type [23]. Interestingly, it was shown before in zebra fish
that the loss of glutaredoxin leads to neuronal apoptosis
and loss of an axonal scaffold, making Grx an essential
protein for embryonic brain development [24].
Several potential neuroprotective agents have been used
in the past to ameliorate the hypoxia/ischemia-induced
damage in the CNS; however, neither of them has shown to
be effective against hypoxia/ischemia-induced damage in
the CNS. Here, we demonstrate the neuroprotective effects
of exogenously administered, recombinantly expressed Grx2
and Trx1 (particularly in the hippocampus) in an animal
model of neonatal hypoxia/ischemia, implying potential
new therapeutic strategies.
2. Experimental Procedures
2.1. Animals. All experiments were conducted according to
the principles of the guide for the care and use of laboratory
animals (NIH publication no. 80-23, revised 1996) and
approved by the institutional animal care and use committee
at the University of Buenos Aires (School of Medicine). All
efforts were made to reduce the number of animals used
and to minimize suffering. Pregnant rats were obtained from
the “School of Veterinary Sciences” central vivarium at the
University of Buenos Aires. All animals were kept in a
temperature (21± 2°C) and humidity (65± 5%) controlled
environment on a 12 h light/dark cycle. Animals had ad
libitum access to food (Purina chow) and tap water.
2.2. Model for Common Carotid Artery Ligation and
Treatment. The model for common carotid artery ligation
used in this study has been previously developed and vali-
dated [23, 25]. P7 male Sprague-Dawley rats were anesthe-
tized (40mg/kg ketamine and 4mg/kg xylazine) and placed
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on a heat plate to keep their body temperature at constant
37°C. The right common carotid artery (CCA) was exposed
through an incision on the neck and was then isolated and
permanently ligated with a 6-0 surgical silk thread (carotid
group n = 27). Afterwards, the wound was closed and pups
were returned to their dams for 4-5 h to recover. Subsequently,
the animals were subjected to a 100%nitrogen environment at
37°C for 3 minutes to induce anoxia. Sham-operated rats
(sham group n = 27) had their right CCA exposed but not
ligated, and no nitrogen was applied. One hour after nitrogen
exposure, animals were injected intraperitoneally (i.p.) with
either saline solution (vehicle group n = 9), 10mg/kg of
recombinantly expressed and purified human Grx2 (Grx2
group n = 9), or 10mg/kg of recombinantly expressed and
purified human Trx1 (Trx1 group n = 9). At 72 h postinjury
(postnatal day 10 (P10)), animals were sacrificed and their
blood plasma and brains were collected for further analysis.
The cloning, recombinant expression, and purification of
hGrx2 and hTrx1 are described in Lundberg et al. [26] and
Godoy et al. [9] and were produced in Dr Lillig’s laboratory.
All human recombinant Grx2 and Trx1 were processed to
exchange the original buffer for phosphate-buffered saline
(PBS) and increase protein concentration. Before injection,
each concentrate was diluted (at least 10-fold) with sterile
saline solution in order to reach a 10mg/kg dosage.
2.3. Western Blotting.Western blot analysis was performed as
previously described in Romero et al. [23]. Animals were
euthanized by decapitation, and brains were dissected,
homogenized in ice-cold lysis buffer (10mM Tris/HCl, pH
7.4, 10mM NaCl, 3mM MgCl2, 0.1% NP-40, protease
inhibitors), and fast frozen in liquid nitrogen. The tissues
were then thawn on ice and centrifuged at 13000 rpm for
15min at 4°C. The supernatants were analyzed for total pro-
tein concentration using Bradford solution (Biorad, Munich,
Germany) in 96-well plates with bovine serum albumin
(BSA) as standard. 10–20μg of total protein were diluted in
sample buffer (0.3M Tris/HCl, pH 7, 50% glycerol, 5%
SDS, 1mM EDTA, 0.1% bromphenol blue) and were treated
with 100mM DTT for 30min at room temperature followed
by 10min at 94°C. Samples were subjected to SDS–PAGE
using the Mini-Protean TGX stain-free 4–20% precast gels
(Biorad) and were transferred to PVDF membranes accord-
ing to the manufacturer’s instructions.
Membranes were blocked with 5% nonfat milk powder
and 1% BSA in Tris-buffered saline containing 0.05% Tween
20 and incubated with specific primary antibodies at 4°C
overnight. Antigen-antibody complexes were stained using
horseradish peroxidase- (HRP-) coupled antibodies (Biorad,
Richmond, CA, USA) and the enhanced chemiluminescence
method. Luminescence was recorded using a gel documen-
tation system (ChemiDoc™ XRS+ System). The total protein
amount in each lane was quantified using the stain-free
technology of Biorad and was used for normalization of the
blotting data obtained from densitometric analysis [27, 28].
Antibodies detecting HSP70 (4873S, dil 1 : 1000) and PSD95
(ab18258, dil 1 : 1000) were purchased from Cell Signaling
Technology (Danvers, USA) and Abcam (Cambridge,
USA), respectively.
2.4. ELISA.A specific sandwich ELISA kit (NS170, Chemicon
International, USA-Canada) was used to quantify the heavy
chain of phosphorylated neurofilaments (pNF-H) accord-
ing to the manufacturer’s instructions. Briefly, a 96-well
immunoplate precoated with chicken anti-pNF-H polyclonal
antibody was used to capture pNF-H in plasma samples, as
well as specific standards with known pNF-H concentrations.
Captured pNF-H was then detected by a rabbit anti-pNF-H
polyclonal antibody (1 : 100) and followed by an alkaline
phosphatase-conjugated goat anti-rabbit polyclonal anti-
body. After the addition of the substrate pNPP (p-nitrophe-
nyl phosphatase), the amount of pNF-H was determined by
absorbance at 405nm.
2.5. Immunohistochemistry and Cell Counting. Immuno-
histochemistry was performed as previously described in
Romero et al. [23]. Animals were anesthetized with 28%
(w/v) chloral hydrate, 0.1ml/100 g of body weight, and
intracardially perfused with 4% paraformaldehyde (Sigma-
Aldrich, St. Louis, MO, USA) freshly prepared in 0.1M phos-
phate buffer, pH 7.4. Brains were dissected and postfixed in
the same solution for 2 h. Coronal brain sections (4μm thick)
were cut using a Leica sliding microtome and then recovered
for light microscopy studies. Prior to the staining, sections
were incubated in 3% hydrogen peroxide for 10min to
quench endogenous peroxidases. After three washing steps
in PBS, nonspecific antibody binding sites were blocked with
10% goat serum (Invitrogen Corporation, Camarillo, CA,
USA) in PBS and sections were incubated overnight with
anti-GFAP rabbit polyclonal antibody (1 : 500, Z0334, Dako,
Germany) at 4°C. Then, sections were washed three times
with PBS and subsequently incubated with a goat anti-
rabbit biotinylated secondary antibody (1 : 500, BA-1000,
Vector Laboratories Inc., USA) for 60min at room tempera-
ture. The streptavidin/HRP detection system (P0397, Dako,
Germany) was used for antigen staining according to the
manufacturer’s recommendations. Sections were incubated
with the substrate diaminobenzidine (11718096001, Roche
Life Science, USA) for 5min at room temperature. Finally,
sections were dehydrated and were mounted with Canada
balsam (Sigma-Aldrich, St. Louis, MO, USA). Sections
without incubation with the primary antibody were used as
a control to verify the specificity of the secondary antibody.
Samples were examined by light microscopy using a Leitz
Laborlux S microscope (Heidelberg, Germany) equipped
with a CCD video camera (Canon). Images were analyzed
and compiled using Adobe Photoshop 11.0 CS4. Note that for
protein staining, all samples (both sham and carotid groups)
were processed together in the same batch, using the same
antibody dilutions and the same time for DAB development.
Cell counting analysis was carried out in 5 to 6 coronal
sections obtained from −3.14mm to −4.30mm Bregma levels
(dorsal hippocampus) [29], for a total of 4 animals per group.
In every section, the number of GFAP positive cells was
quantified in both hemispheres and averaged. A mean was
calculated for each animal and used for subsequent statistical
analysis. We determined the cell number per area using the
“Cell Counter” Image J 1.38X plugin tool (NIH, USA). In sec-
tions stainedwithGFAP containingCornuAmmonis 1 (CA1),
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we set 0.02mm2 squares along the Stratum pyramidale (sp) of
CA1 in such a manner that the whole area was represented.
Subsequently, we manually determined the number of cells
in each square and calculated the number of cells per mm2.
All quantifications were performed in a blind approach.
2.6. Neurobehavioral Studies. Neurobehavioral development
studies were carried out from the first day after hypoxia-
ischemia induction (P8), till the last animal showed the
appearance or disappearance of the analyzed reflex (~P19).
Animals were evaluated every day at the same time (10 a.m.)
for approximately 3 hours each time. All scoring was
performed blindly by two observers. In order to evaluate the
possible effect of the treatment in the neurobehavioral devel-
opment of the animals, pups were subjected to a series of tests
previously described by Kiss et al. [30], Shahrokhi et al. [31],
and Giriko et al. [32], which assess the manifestation of dif-
ferent reflexes such as surface righting reflex, negative geo-
taxis, crossed extensor reflex, ear and eyelid twitching, and
auditory startle. Additionally, ear unfolding and eye opening
were assessed as a measurement of physical development.
2.7. Statistical Analysis. Band intensities obtained from
Western blots were quantified using GelPro 3.1 and were
expressed as percentage of the control levels (sham-operated
rats injected with saline solution). Total protein amount,
visualized using the stain-free technology of Biorad was
quantified using the ImageLab 5.0 software (Biorad). Bar
diagrams depict the mean of four independent quantifica-
tions for each experiment, consisting of sham-operated
(sham-veh, n = 5; sham-Grx2, n = 5; and sham-Trx1, n = 5)
and ischemic (carotid-veh, n = 5; carotid-Grx2, n = 5; and
carotid-Trx1, n = 5) animals + SEM, correlated to total pro-
tein. Two-way ANOVA tests with condition (sham, carotid)
and treatment (vehicle, Grx2, and Trx1) as between-subject
factors, followed by Tukey’s post hoc tests, were employed
to analyze the biochemical parameters and protein levels.
For the neurobehavioral analysis, bar diagrams depict the
mean of the day of appearance of the assessed reflexes for
each group, consisting of sham-operated (sham-veh, n = 10;
sham-Grx2, n = 10; and sham-Trx1, n = 10) and ischemic
(carotid-veh, n = 10; carotid-Grx2, n = 10; and carotid-Trx1,
n = 10) animals + SEM. Kruskal-Wallis tests, followed by
Mann–Whitney tests for pair-wise multiple comparisons,
were employed to analyze neurodevelopmental parameters.
In all cases, the level of significance was set up at 5%. All anal-
yses were performed using SPSS 15.0 (Chicago, IL, USA).
3. Results
We have previously shown that Grx2 and Trx1 are induced
in the hippocampus upon perinatal asphyxia [23]. Interest-
ingly, Grx2 and Trx1 are essential for the neuronal integrity,
since the knock-down of these redoxins in the neuroblastoma
cell line SH-SY5Y affected cell morphology and viability
during hypoxia and reoxygenation [23]. Within this study,
we investigated whether recombinant Grx2 and Trx1 can
be used as therapeutics following perinatal asphyxia, using
the well-established murine carotid ligation model.
3.1. Grx2 Administration Decreases Neuronal Damage after
Neonatal Hypoxia/Ischemia. Perinatal asphyxia was induced
in rats by carotid ligation and 3min nitrogen treatment.
Following the treatment with recombinantly expressed and
purified Grx2, Trx1, or saline solution 1 h after the hypoxic/
ischemic event, animals were sacrificed and their brains
analyzed. We observed that animals from the carotid ligation
group that only received a saline injection displayed an
approximately 3-fold higher immunoreactivity against the
neuronal damage marker heat shock protein 70 (HSP70)
than the sham group with the same treatment (p < 0 01)
(Figure 1). The carotid ligation group treated with recombi-
nant human Grx2 presented an approximately 3-fold lower
immunoreactivity against HSP70 than the carotid ligation
group with saline injection (p < 0 01) and did not differ from
both, the sham group treated with Grx2 nor the sham group
treated with saline solution (Figure 1). Treatment with
recombinant human Trx1 did not affect the protein levels of
HSP70 in both, sham (p < 0 01) and carotid ligation animals
(p < 0 01). The carotid ligation group treated with Trx1 also
presented a 3-fold higher immunoreactivity against HSP70,
comparable to the sham carotid ligation group (Figure 1).
3.2. Exogenous Administration of Grx2 or Trx1 Interferes
with the Glutamate Excitotoxicity Pathway after Neonatal
Hypoxia/Ischemia. To determine whether Grx2 or Trx1
treatments affect the excitotoxic effects of glutamate associ-
ated with PA, we analyzed the protein levels of the postsynap-
tic density protein 95 (PSD95). High levels of PSD95 have
been linked to increase glutamate excitotoxicity, while its
reduction has been linked to a neuroprotective effect in neo-
natal models of hypoxia/ischemia [33–35]. Western blotting
analysis showed that animals subjected to neonatal hypoxia/
ischemia and injected with saline solution presented over
5-fold higher levels of PSD95 in comparison to the sham
group with the same treatment (p < 0 01) (Figure 2). After
injection of 10mg/kg of Grx2 1 hour after the hypoxic/ische-
mic insult, the carotid ligation group displayed no differences
compared to the sham group that was also treated with Grx2.
Furthermore, neither the sham group nor the carotid group
treated with Grx2 showed any significant differences when
compared to the sham group that only received the saline
injection (Figure 2). The carotid ligation group treated with
Grx2 presented an approximately 6-fold reduction in the
levels of PSD95 compared with the saline-treated carotid
ligation group (p < 0 01) (Figure 2). The carotid ligation
group treated with Trx1 presented a 3-fold increase in
PSD95 levels in comparison to both the sham group treated
with Grx2 (p < 0 05) and the sham group with saline injec-
tion (p < 0 05). Nonetheless, Trx1 treatment significantly
attenuated the increase in PSD95 levels in the carotid ligation
group by 3-fold in comparison to the carotid group treated
with saline solution (p < 0 01) (Figure 2).
3.3. Exogenous Administration of Grx2 or Trx1 Helps in
Maintaining Structural Integrity after Neonatal Hypoxia/
Ischemia. The structural integrity of axons was evaluated in
hypoxic/ischemic animals 72 h after the hypoxia/ischemia
event by analyzing the plasma levels of phosphorylated
4 Oxidative Medicine and Cellular Longevity
neurofilament heavy protein (pNF-H). In fact, animals of the
CCA ligation group with the saline injection had a 50%
increase in the levels of pNF-H in plasma in comparison to
the sham group treated only with saline solution (p < 0 05)
(Figure 3). Animals subjected to an injection of 10mg/kg of
Grx2 one hour after the hypoxic/ischemic event did not show
the increase in pNF-H levels in plasma normally associated
with structural axon damage. Moreover, both the carotid
ligation and sham groups treated with Grx2 did not display
differences in the levels of pNF-H, compared to the sham
group that only received a saline injection (Figure 3). Simi-
larly, animals from the carotid ligation group treated with
Trx1 did not present an increase in pNF-H plasma levels.
Interestingly, the levels of pNF-H in plasma in the groups
treated with Trx1 were still another 50% lower than those
detected in the sham group that only received a saline
injection (p < 0 05) (Figure 3).
3.4. Exogenous Administration of Grx2 and Trx1 Avoids the
Astrogliosis Caused by Neonatal Hypoxia/Ischemia. The effect
of Grx2 and Trx1 treatment on astrogliosis development
following the hypoxic/ischemic event was analyzed by glial
fibrillary acidic protein (GFAP) immunostaining in the
stratum radiatum of the hippocampal CA1 area, which
previously has been reported as a particularly susceptible area
in neural plasticity and development of astrogliosis [36–38].
As expected, hypoxic/ischemic rats injected with saline solu-
tion presented an approximately 30% increase in the number
of GFAP positive (GFAP+) astrocytes, in comparison to
sham rats treated with saline solution (p < 0 01) (Figure 4).
Animals from the carotid ligated group treated with Grx2
did not present an increase in the number of GFAP+ cells
when compared to the carotid ligated group treated with
saline solution (p < 0 05), while it did not show any differ-
ences in comparison with the sham group treated with
Grx2 (Figure 4). Likewise, the carotid group treated with
Trx1 did not show an increase in GFAP+ astrocytes in
comparison to the carotid group that only received the
saline solution injection (p < 0 01). No significant differ-



















































Figure 2: Grx2 and Trx1 interfere with the glutamate excitotoxicity
pathway following neonatal hypoxia/ischemia. Perinatal asphyxia
was induced in rats by carotid ligation and 3min nitrogen
treatment. During 1 h postischemia, the animals were treated with
recombinant Grx2 or Trx1. Hippocampi were isolated and
analyzed for changes in the protein levels of PSD95 by Western
blot, as a reporter for the induction of glutamate exitotoxicity. The
diagram depicts the relative protein levels compared to sham-
operated rats that only received a saline solution (vehicle). Bars
show the mean + SEM of 5 rats per group. Two-way ANOVA test
[condition (sham, carotid): F 1,24 = 29 07, p < 0 001; treatment
(veh, Grx2, and Trx1): F 2,24 = 58 36, p < 0 05; and interaction:
F 2,24 = 10 61, p < 0 001] followed by Tukey’s post hoc tests was














































Figure 1: Grx2 reduces neuronal damage following perinatal
hypoxia/ischemia. Perinatal asphyxia was induced in rats by carotid
ligation and 3min nitrogen treatment. During 1 h postischemia, the
animals were treated with recombinant Grx2 or Trx1. Hippocampi
were isolated and analyzed for changes in the protein levels of the
neuronal damage marker HSP70 by Western blot. The diagram
depicts the relative protein levels compared to sham-operated
rats that only received a saline solution (vehicle). Representative
Western blots demonstrate the significant changes. Bars depict
the mean + SEM of 5 rats per group. Two-way ANOVA test
[condition (sham, carotid): F 1,24 = 49 85, p < 0 001; treatment
(veh, Grx2, and Trx1): F 2,24 = 8 05, p < 0 01; and interaction:
F 2,24 = 8 39, p < 0 01] followed by Tukey’s post hoc tests was
employed to analyze the data. ∗∗p < 0 01.
5Oxidative Medicine and Cellular Longevity
groups treated with Trx1 (Figure 4). Moreover, all groups
treated with either Grx2 or Trx1 did not show significant
differences when compared with the sham group treated
only with the saline solution (Figure 4), suggesting that
the treatment with either Grx2 or Trx1 protects from the
astrogliosis associated with the hypoxic/ischemic event
during birth.
3.5. Grx2 and Trx1 Administration Reverts Some of the
Early Developmental Alterations Associated with Neonatal
Hypoxia/Ischemia. In order to assess both the effects of
the hypoxic/ischemic event and the treatment with Grx2 or
Trx1 on the neurodevelopment of pups, a series of reflexes
and physical developmental parameters were measured from
postnatal day 8 (P8) until ~P19. There were no significant
differences between group conditions (sham or carotid) or
between treatments (saline, Grx2, or Trx1 administration)
for the tasks evaluating surface righting reflex, negative
geotaxis, crossed extensor reflex, ear twitching, auditory
startle, and ear unfolding (see Supplementary Figure 1 avail-
able online at https://doi.org/10.1155/2017/4162465). Never-
theless, carotid animals that only received a saline injection
displayed a significant delay in eye opening and eyelid twitch-
ing in comparison with sham-operated animals (p < 0 05 in
both cases, see Figures 5(a) and 5(b), resp.). Interestingly,
Grx2 administration reverted the delayed eye opening
observed in the carotid group treated with saline
(Figure 5(a)). Trx1 administration had no effect on this devel-
opmental parameter. Interestingly, Grx2 had no effect on the
delay in eyelid twitching observed after the injury, while Trx1
treatment reverted the delay in relation with the sham group
(Figure 5(b)).
4. Discussion
Recently, we have analyzed the changes in the levels of
14 members of the Trx family in the brains of rats subjected
to the carotid ligation model [23], showing that Grx2 and
Trx1 are crucial for the recovery following hypoxia/ischemia
and reoxygenation. In fact, silencing of these proteins in
neuron-like cell cultures (SH-SY5Y) plays an important role
in maintaining the neuronal phenotype of these cells [23].
These studies prompted us to investigate the effects of
protein administration on the neuronal damage caused by
PA. The results presented suggest that the administration of
Grx2, and to some extent the administration of Trx1, has
the potential to significantly attenuate the neuronal damage
caused by PA, including the cellular damage response, gluta-
mate excitotoxicity, axonal integrity, and astrogliosis. It is
worth mentioning that the reoxygenation phase following a
hypoxic/ischemic event comprises the early, acute phase that
is induced by O2, O2−, and overall changes in cellular redox
properties, and the late subacute phase that is rather
induced by the overall immune response [39]. Here, we
have focused on the short-term changes (72 h posthypoxic/
ischemic event) induced by PA, because (i) the CNS is
especially susceptible to oxidative damage due to its high
metabolic rate, its oxygen consumption, and its low capacity
for regeneration and (ii) these changes correlate with the
mortality rate of patients [40–43].
Interestingly, Prxs, substrates for Trxs and Grxs, are
significantly altered as a result of stroke-related insults
[21, 44–46]. Overexpression of Prx6 decreased hypoxia-
induced retinal ganglion cell death [47]. Prx3, which was
shown to be reduced and regenerated by Grx2 [48], showed
elevated protein levels in the hippocampus of gerbils
following cerebral hypoxia/ischemia and reoxygenation and
protected CA1 pyramidal neurons against the induced dam-
age [49]. It is thus tempting to speculate that the protective
mechanism of Grx2 could involve the reduction of Prxs and
therefore the regulation of intracellular levels of peroxides
and cellular signaling, as well as the molecular damage that
can occur in the presence of high peroxide levels.
Cellular damage derived from an ischemic insult induces
the expression of heat shock proteins, one of the groups of
proteins involved in the overall stress response [50]. HSP70
is constitutively expressed and is the most abundant heat
shock protein present in the cell, and it is produced as a
response to several stimuli, such as heat, heavy metals, toxins,
and ischemia [51]. Increased HSP70 expression has been
reported as a response to ischemic damage in neurons,
astrocytes, and endothelial cells [52]. Interestingly, cerebral


























Figure 3: Grx2 and Trx1 help to maintain the structural integrity
following neonatal hypoxia/ischemia. Plasma from 10-day-old
rats that were subjected to a carotid ligation or sham operation
and subsequent 3min nitrogen treatment and received a
treatment with either saline solution, Grx2, or Trx1 one hour
postinjury, was screened for pNF-H as a measurement of
structural damage to the axons. The levels of pNF-H were
analyzed by a specific ELISA. Bars represent the mean + SEM of
5 rats per group. Two-way ANOVA test [condition (sham,
carotid): F 1,24 = 27 20, p < 0 001; treatment (veh, Grx2, and
Trx1): F 2,24 = 53 34, p < 0 001; and interaction: F 2,24 = 7 47,
p < 0 01] followed by Tukey post hoc tests was employed to
analyze the data. ∗p < 0 05, ∗∗p < 0 01.
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hippocampus and the cerebral cortex, correlating with the
vulnerability of the CNS to ischemic damage [53]. Since
carotid animals that were treated with Grx2 presented signif-
icantly lower levels of HSP70 compared to control animals
that only received saline solution, it can be inferred that
Grx2 can significantly reduce the immediate cellular response
towards the hypoxic/ischemic event associated with the
HSP70 response (Figure 1).
The protein-protein interactions, mediated by the PPDZ
domain of the postsynaptic density 95 protein, are key
elements in intracellular signaling [54]. The structural




























Figure 4: Grx2 and Trx1 prevent the characteristic astrogliosis that follows neonatal hypoxia/ischemia. (a) Representative immunostainings
of GFAP in the CA1 area of the hippocampus. Insets show the morphological details of astrocytes. (b) Quantification of GFAP+ cells as
number of positive cells by mm2 was used as a measurement of the reactive gliosis response. Bars represent the mean + SEM of 4 rats per
group. Two-way ANOVA test [condition (sham, carotid): F 1,18 = 17 52, p < 0 001; treatment (veh, Grx2, and Trx1): F 2,18 = 7 42,
p < 0 001; and interaction: F 2,18 = 3 97, p < 0 05] followed by Tukey’s post hoc tests was employed to analyze the data. ∗∗p < 0 01. Scale
bars 10 μm.
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ionotropic glutamate receptor NMDA and the enzyme
nNOS through its PDZ1 and PDZ2 domains [55]. The
activation of the NMDA receptor causes the influx of intra-
cellular Ca2+ which, in turn, produces the activation of nNOS
with the consequent generation of NO [35], one of the most
common promoters of glutamate excitotoxicity [56, 57].
Considering that PSD95 inhibition does not affect the overall
ion flux [58] or the signaling pathways that favor survival
[59], which are mediated by the NMDA receptor, it has been
speculated that PSD95 could be a safe and efficient target for
the treatment of cerebral ischemic damage [60]. Hence, neu-
rons deficient for PSD95 or nNOS show a reduction in the
vulnerability to glutamate excitotoxicity [61]. Previous stud-
ies have shown that the reduction of PSD95 expression is
linked to a reduction of the damage associated with a neona-
tal hypoxic/ischemic event [33–35]. As expected, the levels of
PSD95 were significantly elevated in the carotid group com-
pared to the sham animal group (about 7-fold increase).
Interestingly, no significant increase of PSD95 was detected
in the carotid animals injected with Grx2 compared to the
sham animal groups injected with saline solution or Grx2.
Thus, Grx2 might not only counteract the HSP70 response
but also the damage associated to glutamate excitotoxicity
after the hypoxic/ischemic injury (Figure 2). Even though
Trx1 treatment did not show a significant effect on HSP70
protein levels following the hypoxia/ischemia (Figure 1), a
significant 3-fold decrease in the protein levels of PSD95
compared with the carotid group treated with saline solution
was detected. However, Trx1 treatment was not as efficient as
Grx2 in preventing or counteracting the induction of PSD95
(Figure 2).
The screening of specific components in tissues and
biological fluids secreted upon pathological conditions is
commonly used as a therapeutic and diagnostic tool [62].
Neurofilaments are highly abundant proteins in neurons
and are found in the axons of all neurons. Their main
function is the maintenance of the axonal gauge, which is
essential for the morphological integrity and the conduction
velocity of neuronal impulses [63]. Three types of neurofila-
ments (light neurofilaments (NF-L), medium neurofilaments
(NF-M), and heavy neurofilaments (NF-H)) make up the
nerve fibers and are eliminated to the extracellular space in
considerable amounts following axonal damage or neuronal
degeneration [64–66]. The perturbation of the axonal mem-
brane expels neurofilaments to the interstitial space and
eventually to the cerebrospinal fluid and the blood. In this
manner, the levels of neurofilaments in the blood can be used
for both the prediction and monitoring of the progress of a
disease and the evaluation of the efficacy and/or toxicity of
neuroprotective treatments [67–70]. The phosphorylated
form of NF-H is axon-specific and is used as a specific
marker for neuronal damage and degeneration [71]. pNF-H
levels are, for instance, elevated following acute hypoxic/
ischemic damage [72]. It has been further shown that the levels
of pNF-H in serum and cerebrospinal fluid are increased after
a variety of damages to the CNS, both in animal models and
in humans [71]. Moreover, the increment of pNF-H levels in
serum is a good indicator of the degree of the lesion in the
white matter of the CNS [73]. In our model, we could con-
firm that acute hypoxia/ischemia leads to neuronal damage
and elevated levels of pNF-H in serum compared to sham
animals (Figure 3). Interestingly, when the carotid animals
were treated with Grx2 or Trx1 following the hypoxic/
ischemic event, no such increase was detectable via specific
ELISA (Figure 3). It is worth to notice that in the case of








































Figure 5: Grx2 and Trx1 revert the delay in the appearance of eye neurodevelopment milestones present after neonatal hypoxia/ischemia.
Pups were evaluated for the detection of variation in the appearance of different reflexes and motor skills. (a) Quantification of the eye
opening in pups expressed as the day of the first appearance (both eyes presented completed separation of the eyelids). (b) Quantification
of the eye twitching reflex in pups expressed as the day of the first appearance (day in which both eyelids twitch for the first time). Bars
represent the mean + SEM of 10 rats per group. Kruskal-Wallis tests [eye opening: H= 25.35, d.f. = 5, p < 0 001; eye twitching: H= 15.72,
d.f. = 5, p < 0 01], followed by post hoc Mann–Whitney tests were employed to analyze the data. ∗p < 0 05, ∗∗p < 0 01.
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carotid animals were well below those found in the sham
group treated only with saline solution. This effect could
be the consequence of a higher effect in axonal integrity
produced by Trx1. In this regard, previous studies have
linked Trx1 to a strong protection against axonal damage
in a model of retinal nerve damage [74, 75], as well as to
the regulation of axonal regeneration [76]. The excess of
Trx1 in the system could thus contribute to lower the basal
levels of pNF-H by tipping the balance toward axonal regen-
eration rather than disruption.
Reactive gliosis can be triggered in response to several
CNS pathologies, such as trauma, stroke, and neurodegener-
ative diseases [77]. Following injury, astrocytes proliferate
and their GFAP expression increases [78]. Experimental data
suggest that reactive gliosis can be detrimental for neuroplas-
ticity and regeneration of the CNS. Therefore, the prevention
of reactive gliosis has become an essential issue in the
development of therapeutic interventions [79]. Previous
studies have shown that perinatal hypoxia/ischemia triggers
reactive gliosis in neonatal rats [36, 80]. In this study, we have
shown that hypoxia/ischemia induces the characteristic
reactive gliosis. Sham-treated animals, as well as animals that
were treated with either Grx2 or Trx1 one hour after the
injury, did not develop astrogliosis (Figure 4).
The rat postnatal development is characterized by the
appearance of a series of reflexes and motor skills through
the first three weeks of life [81]. During this period, differ-
ent insults, such as a hypoxic/ischemic event, can affect
the normal development of those reflexes and physical
skills [30, 82–84]. Previous studies have shown that glutamate
neurotoxicity plays a key role in the impairment of the devel-
opment of neurological reflexes andmotor skills [82, 85]. This
excitotoxicity has shown to be most severe in the retina, in
the cortex, and in the hippocampus [82, 85–88]. Moreover,
glutamate excitotoxicity has also been previously linked to
neurobehavioral delays [82, 85]. Interestingly, the bioche-
mical findings of this study showed that both Grx2 and
Trx1 acted in the biomarker reduction associated with the
glutamate excitotoxicity pathway which was increased after
hypoxia/ischemia (Figure 2). In this regard, neurodevelop-
mental analyses have shown that Grx2 treatment was able
to revert the developmental delay presented in the opening
of the eye in carotid pups (Figure 5(a)), while Trx1 adminis-
tration reverted the neurodevelopmental delay presented in
the appearance of the eye twitching reflex (Figure 5(b)).
Both of the thioredoxin family proteins investigated here,
Grx2 and Trx1, have been characterized as crucial for cell
survival under various conditions when expressed intracellu-
larly (summarized, for instance in Holmgren et al. [89] and
Hanschmann et al. [6]). Since Trx1 is known to be secreted
by cells via an unconventional mechanism and to function,
for instance, in the activation of immune cells (summarized
in Nakamura [90]), Trx1 administration has been discussed
as a potential therapeutic strategy against cellular damage
[91]. In fact, the perfusion, but not the inhalation, of recom-
binant human Trx1 protected rat lungs from ischemia-
reperfusion injury [92]. An intravitreous injection of recom-
binant Trx1 was also shown to attenuate the damage pro-
duced to the retina by ischemia and glaucoma, induced
by N-methyl-D-aspartate, which stimulates glutamate
receptors [93]. Both Grxs and Trxs have shown to protect
from dopamine-induced neuronal damage in vitro [94, 95].
Recently, Tian and coworkers demonstrated that treatment
with recombinant Trx1 can improve the neurogenesis via
the regulation of the ERK signaling pathway in mice follow-
ing global cerebral ischemia, improving spatial learning and
memory [22].
In the present study, we have shown that even though
Grx2 and Trx1 are both part of the thioredoxin family of
proteins, they do not necessarily behave in the same manner.
This can be exemplified by the differences observed in
response to Grx2 and Trx1 treatments, regarding HSP70,
PSD95, and pNF-Hmarkers as well as the different outcomes
in the neurodevelopmental evaluation after the treatments.
These differences could be explained through the possible
distinct mechanisms involved in each protein intervention.
In this regard, it is known that Grx2, as part of the glutare-
doxin subfamily, plays a key role in redox-dependent cellular
processes [96]. Particularly, glutaredoxins (Grxs) are able to
reduce both disulfides and mixed disulfides, while they
can be restored by glutathione reductase which is directly
coupled to the GSH/GSSG ratio (the main indicator of
the cell redox state and its redox potential) [97, 98]. Grxs are
also capable of catalyzing S-glutathionylation of proteins (a
key regulatory mechanism of biological processes) [99, 100].
It is generally accepted that Grxs are a key component in
response to an oxidative imbalance through the regulation
of mix disulfides [101, 102]. In addition, due to the mito-
chondrial localization of Grx2, it has been proved that it
prevents apoptosis by avoiding the leak of cytochrome c from
mitochondria and cardiolipin oxidation [89, 103, 104]. By
contrast, Trx1 shows no activity towards mixed disulfides
and it is thought to have a more prominent role in redox reg-
ulation of cell signaling rather than direct participation in
redox-dependent reactions as a consequence of its low levels
in comparison with other endogenous antioxidants, and its
multifunctional role as a cytosolic protein. In this compart-
ment, Trx1 can function as a growth factor and enzyme cofac-
tor and, under different stresses, can translocate to the nucleus
and regulate several transcription factors [96, 105–109].
Taking this data into account, the observed differences in the
measurements performed in the present study could be
associated with the biological processes in which each
redoxin is more important. One could hypothesize that those
processes more related to an imbalance of the redox state
could respond better to a Grx2 treatment, while Trx1 could
be more prominent in processes where it functions as a reg-
ulator of transcription factors.
5. Conclusion
Taken together, the results presented in this study suggest
that the delivery of recombinant Grx2, and to some extend
of Trx1, has the potential to attenuate the severe neurological
damage induced by PA. If not the delivery of these proteins
themselves, a detailed understanding of the underlying redox
regulated signaling pathways, may put in evidence the need
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for new therapeutic strategies to improve CNS recovery after
PA and potentially other stroke associated pathologies.
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